Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting-Reference-Cited by-同舟云学术

Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting

Published:2022-04-28 Issue:17 Volume:386 Page:1603-1614
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Magen Ori¹,Waxman Jacob G.¹,Makov-Assif Maya¹,Vered Roni¹,Dicker Dror¹,Hernán Miguel A.¹^ORCID,Lipsitch Marc¹^ORCID,Reis Ben Y.¹^ORCID,Balicer Ran D.¹,Dagan Noa¹^ORCID

Affiliation:

1. From the Clalit Research Institute, Innovation Division (O.M., J.G.W., M.M.-A., R.D.B., N.D.), and the Tel-Aviv District, Community Division (R.V.), Clalit Health Services, and the Sackler Faculty of Medicine, Tel-Aviv University (D.D.), Tel Aviv, the Department of Internal Medicine D, Hasharon Hospital Rabin Medical Center, Petah Tikva (D.D.), and the School of Public Health, Faculty of Health Sciences (R.D.B.), and the Department of Software and Information Systems Engineering (N.D.), Ben Gurion...

Funder

the Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at Harvard Medical School and Clalit Research Institute

Morris-Singer Fund

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2201688

Reference10 articles.

1. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

2. Protection by a Fourth Dose of BNT162b2 against Omicron in Israel